Skip to main contentSkip to navigationSkip to navigation
The new Covid Omicron subvariants BA.4, BA.5 and BA2.12.1 are likely to displace BA.1 and BA.2 in Australia.
The new Covid Omicron subvariants BA.4, BA.5 and BA2.12.1 are likely to displace BA.1 and BA.2 in Australia. Photograph: Carly Earl/The Guardian
The new Covid Omicron subvariants BA.4, BA.5 and BA2.12.1 are likely to displace BA.1 and BA.2 in Australia. Photograph: Carly Earl/The Guardian

Three new Covid Omicron subvariants detected in Australia

This article is more than 1 year old

BA.2.12.1, BA.4 and BA.5 found as authorities warn winter is likely to bring a spike in coronavirus cases

Three new Omicron subvariants have reached Australia and health authorities say people who contract the virus should wait three months before getting their next Covid-19 vaccination.

Assoc Prof Stuart Turville from the University of New South Wales’ Kirby Institute says Omicron subvariants BA.2.12.1, BA.4 and BA.5 have been detected in the country.

Authorities are warning this winter season is likely to see a spike in Covid-19 cases and flu as restrictions which have suppressed the circulation of both viruses are phased out.

The latest advice from the Australian Technical Advisory Group on Immunisation recommends people wait three months after a confirmed Covid-19 infection and then receive their next vaccine dose as soon as possible.

The advice, issued last week, applies to all people and for all Covid-19 vaccines.

Turville said the severity and transmissibility of the new Omicron subvariants had yet to be determined.

The arrival of Omicron BA.1 and BA.2 were marked by their ability to significantly evade a previous antibody response through past infection and/or vaccination, but the impact was less severe.

Sign up to receive an email with the top stories from Guardian Australia every morning

The new subvariants BA.4, BA.5 and BA2.12.1 are likely to displace BA.1 and BA.2 in Australia.

“We will need to study this over time to see if their advantage is one of “fitness/transmissibility” and/or their ability to be more slippery to existing antibodies,” Turville said. “As with all variants, the key parameter to watch is disease severity and this data takes time to accumulate.

“There is still a lot about this virus that is unknown and there are many paths it has the potential to take.”

Most viewed

Most viewed